Results 41 to 50 of about 873,641 (211)

Neurochemical Endpoints to Inform Early‐Stage Trials of Spinocerebellar Ataxia 2 and 3 in a Multisite Setting

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Neurochemical levels measured by brain MR spectroscopy (MRS) have been proposed as endpoints for clinical trials in early‐stage spinocerebellar ataxia (SCA) trials. We tested their trial‐readiness by quantifying neurochemicals in three affected brain regions in early‐stage cohorts of SCA2 and SCA3, examining their reproducibility in ...
James M. Joers   +19 more
wiley   +1 more source

Impact of Brand Loyalty on Brand Extension [PDF]

open access: yes, 2012
The key objective of this study is to explore the effects of different dimensions of brand loyalty towards the original brand on the evaluation of brand extensions.
Ahmed Imran , Hunjra   +3 more
core   +1 more source

The CLA HE Trial Scanning Licence : how we’re using it [PDF]

open access: yes
The Copyright Licensing Agency (CLA) Higher Education (HE) Trial Scanning Licence has been implemented to varying degrees across UK HE institutions. The UK HE community has sought to share expertise in the technical, practical and compliance issues ...
Delasalle, Jenny
core  

Bi‐ and Mono‐Allelic RFC1 Expansion in a North American Cohort With Idiopathic Axonal Neuropathy

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective RFC1 biallelic repeat expansion is increasingly recognized as a cause of chronic idiopathic axonal polyneuropathy (CIAP), but it remains challenging to know who to test. This study aims to determine the prevalence of biallelic and monoallelic RFC1 expansions and their corresponding neuropathy phenotypes in CIAP patients and identify ...
Amro M. Stino   +25 more
wiley   +1 more source

Digital Cognitive Testing in Mitochondrial Disease: Validity and Challenges for Clinical Trial Use

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Primary mitochondrial disease is a group of genetic disorders caused by pathogenic variants in nuclear or mitochondrial DNA, often resulting in progressive neurodegeneration and cognitive decline. Current management is primarily supportive, though recent research offers hope for disease‐modifying treatments in the future.
Oksana Pogoryelova   +9 more
wiley   +1 more source

Factors Associated With the Rising Trend in Self‐Reported Cognitive Disability Among U.S. Adults Aged 18–39 From 2013–2024

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objective Building on our prior Behavioral Risk Factor Surveillance System analysis identifying adults aged 18–39 as the primary driver of the national increase in self‐reported cognitive disability, we examined factors associated with this rise using 2013–2024 U.S. BRFSS data. Methods We analyzed U.S.
Adam de Havenon   +9 more
wiley   +1 more source

The Role of Licence-Exemption in Spectrum Reform [PDF]

open access: yes
Spectrum reform initiatives in the US and Europe have identified a need to move away from the traditional command and control approach towards flexible and tradable licences and licence-exemption.
De Vries, Gary, De Vries, Pierre
core  

Modern Management of Asymptomatic Carotid Stenosis: A Meta‐Analysis of CREST‐2, SPACE‐2, and ECST‐2

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Background Recent randomized trials (CREST‐2, SPACE‐2, and ECST‐2) have compared carotid revascularization (carotid endarterectomy [CEA] or carotid artery stenting [CAS]) plus contemporary medical therapy (CMT) versus CMT alone in asymptomatic carotid stenosis.
Aasim Ali   +14 more
wiley   +1 more source

WTO Agreements on SPS & TBT: Implications for Food Quality Issues [PDF]

open access: yes
Trade liberalization, hoped to be achieved through WTO Agreement on Agriculture (AoA) is expected to lead to export promotion and import substitution opportunities for Indian food sector.
Deodhar, Satish Y.
core  

Vascular Disease, Non‐Steroidal Anti‐Inflammatory Drugs and Risk of Parkinson's Disease

open access: yesAnnals of Clinical and Translational Neurology, EarlyView.
ABSTRACT Objectives A history of vascular disease has been shown to be associated with an increased risk of Parkinson's disease, but this may be due to reverse causation. In addition, non‐steroidal anti‐inflammatory drugs are thought to reduce Parkinson's disease risk, but evidence is inconsistent and confounding by prior vascular disease is possible ...
Clare Wotton   +4 more
wiley   +1 more source

Home - About - Disclaimer - Privacy